SWX:SDZPharmaceuticals
Sandoz (SWX:SDZ) Stock Profit Rebound Sharpens Focus On Rich P/E
Sandoz Group shareholders walked into this earnings day with a stock that had inched higher over the past week but gone essentially sideways over the past month. The market is still trying to decide whether a rich P/E of 57.2x belongs on a generics and biosimilars specialist or on a high growth story that just happens to sell off patent drugs.
H1 2026 results gave that debate fresh fuel. Net sales reached about US$5.8b with a core earnings before interest, tax, depreciation and amortisation...